Bergenbio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for aggressive diseases, primarily targeting cancer and severe respiratory infections. The company is a leader in the development of AXL inhibitors, seeking to address the underlying mechanisms that drive drug resistance, metastasis, and immune evasion in cancers. Its flagship molecule, bemcentinib, is an orally administered, selective AXL receptor tyrosine kinase inhibitor, progressing through multiple clinical trial phases for indications such as non-small cell lung cancer and acute myeloid leukemia. BerGenBio’s research pipeline also includes tilvestamab, a monoclonal antibody designed to block AXL function, and mipasetamab uzoptirine, aimed at various solid tumors. By focusing on AXL as a therapeutic target, the company aims to provide new treatment options where current therapies are limited, particularly for patients with hard-to-treat, relapsed, or resistant cancers. Headquartered in Bergen, Norway, BerGenBio plays a pioneering role in advancing targeted oncology and immunotherapy solutions within the biotechnology sector.